1. Human iPS cell-derived dopaminergic neurons can be induced from both healthy individuals and patients with Parkinson's Disease, and when grafted into the striatum of MPTP-treated cynomolgus monkeys, can improve impaired behaviour.
2. The donor cells showed no signs of tumorigenic cells, and the transplantation was found to be safe with no abnormal behaviour such as dyskinesia observed.
3. The extent of recovery after cell transplantation was similar in terms of neurological score and lower in terms of spontaneous movement than that produced by high dose l-DOPA administration.
The article is generally reliable and trustworthy, as it provides evidence for its claims through experiments conducted on cynomolgus monkeys, which are a good model for studying human diseases due to their close genetic similarity to humans. The article also provides detailed information about the methods used in the experiments, such as MRI imaging and PET scans, which adds to its credibility.
However, there are some potential biases that should be noted. Firstly, the sample size used in the study is relatively small (n=3 for vehicle and PD groups; n=4 for healthy group), which may not be sufficient to draw definitive conclusions about the efficacy of cell transplantation in treating Parkinson's Disease. Secondly, all experiments were conducted on cynomolgus monkeys rather than humans, so further studies should be conducted on humans before any definitive conclusions can be drawn about the efficacy of cell transplantation in treating Parkinson's Disease in humans. Thirdly, there is a lack of discussion about possible risks associated with cell transplantation such as immune rejection or adverse effects from immunosuppressant drugs used during the procedure. Finally, there is a lack of discussion about alternative treatments for Parkinson's Disease such as deep brain stimulation or gene therapy that could potentially provide better outcomes than cell transplantation.